Investor Presentaiton
Company overview
Financial performance
Financial review
2022 priorities
Innovation: Pipeline overview
Novartis pipeline in Phase 3
Solid Tumors
Hematology
Appendix
Innovation: Clinical trials
References
Abbreviations
8 lead indications
Lead indication
Mechanism
BCR-ABL inhibitor
CD19 CAR-T
Thrombopoietin receptor
(TPO-R) agonist
CFB inhibitor
Indication(s)
Chronic myeloid leukemia, 1st line
1L high risk acute lymphocytic leukaemia, pediatrics & young adults
Radiation sickness syndrome
Paroxysmal nocturnal haemoglobinuria
Atypical haemolytic uraemic syndrome
Myelodysplastic syndrome
2L Diffuse large B-cell lymphoma4)
Code
AAA617
Name
Mechanism
Indication(s)
Code
Name
PluvictoⓇ
Radioligand therapy target PSMA mCRPC, pre-taxane
ABL001
Scemblix
AAA6011) Lutathera®
Metastatic hormone sensitive prostate cancer (mHSPC)
Radioligand therapy target SSTR Gastroenteropancreatic neuroendocrine tumors, 1st line in G2/3
tumors (GEP-NET 1L G3)
CTL019
ETB115
KymriahⓇ
Promacta®
ACZ885
canakinumab
IL-1b inhibitor
NSCLC, adjuvant
LNP023
iptacopan
BYL719
JDQ443
Piqray®
JDQ443
PI3Ka inhibitor
HER2+ adv BC
Triple negative breast cancer Ovarian cancer
KRAS inhibitor
2/3L Non-small cell lung cancer
MBG453 sabatolimab
YTB323 YTB323
TIM3 antagonist
CD19 CAR-T
LEE011
Kisqali®
CDK4 Inhibitor
NIS793
NIS793
TGFB1 inhibitor
VDT482
Tislelizumab
PD1 inhibitor
HR+/HER2- BC (adj)
1L Nasopharyngeal Carcinoma
1L ESCC
1L Metastatic pancreatic ductal adenocarcinoma
Adj/Neo adj. NSCLC
Immunology
Code
1L Hepatocellular Carcinoma
1L Gastric cancer
Localized ESCC
1L Urothelial Cell Carcinoma
1L Small Cell Lung Cancer
AIN457
Name
Cosentyx®
Mechanism
IL17A inhibitor
IgE inhibitor
LOU064 remibrutinib
QGE031 ligelizumab
VAY736 ianalumab
BTK inhibitor
BAFF-R inhibitor
Indication(s)
Lupus Nephritis
Psoriatic arthritis (IV formulation)
Axial SpA (IV formulation)
Giant cell arteritis
Chronic spontaneous urticaria
Food allergy
Lupus Nephritis³)
Neuroscience
Code
Name
AMG334 AimovigⓇ
BAF312 MayzentⓇ
LOU064 remibrutinib
OAV101 AVXS-101
OMB157 KesimptaⓇ
Mechanism
CGRPR antagonist
S1P1,5 receptor modulator
BTK inhibitor
Indication(s)
Migraine, pediatrics
Multiple sclerosis, pediatrics
Multiple sclerosis
SMN1 gene replacement therapy SMA IT administration
CD20 Antagonist
Multiple sclerosis, pediatrics
1. 177 Lu-dotatate in US 2. Approved in US
3. Ph3 initiating
4. Ph3 to be initiated pending strategy update
41 Investor Relations | Q2 2022 Results
Cardio-renal
Code
Name
KJX839 Leqvio®
LCZ696 EntrestoⓇ
Mechanism
siRNA (regulation of LDL-C)
Angiotensin receptor/neprilysin
inhibitor
LNP023
iptacopan
CFB inhibitor
TQJ230 Pelacarsen
ASO targeting Lp(a)
Indication(s)
CVRR-LDLC
Hyperlipidemia, pediatrics
Congestive heart failure, pediatrics²)
IgA nephropathy
C3 glomerulopathy
Secondary prevention of cardiovascular events in patients with
elevated levels of lipoprotein (a) (CVRR-Lp(a))
Others
Code
Name
Mechanism
Global Health
COA566 Coartem®
Respiratory & Allergy
IGE025 Xolair®
IgE inhibitor
Ophthalmology
RTH258 BeovuⓇ
Biosimilars
Code Name
GP2411 denosumab
SOK583 aflibercept
Indication(s)
VEGF inhibitor
Malaria, uncomplicated (<5kg patients)
Food allergy
Diabetic retinopathy
Auto-injector
Mechanism
anti RANKL mAb
VEGF inhibitor
Indication(s)
Osteoporosis (same as originator)
Ophthalmology indication (as originator)
U NOVARTIS | Reimagining MedicineView entire presentation